Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 35Bevacizumab 31Carboplatin 29pembrolizumab 25Specimen Handling 20Magnetic Resonance Spectroscopy 18olaparib 16Cisplatin 15liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 8fludarabine 7Doxorubicin 7mirvetuximab soravtansine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4durvalumab 4cediranib 4Platinum 4Megestrol Acetate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
disitamab vedotin × Gynecologic × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡